GlaxoSmithKline Pharmaceuticals Statistics
Total Valuation
GlaxoSmithKline Pharmaceuticals has a market cap or net worth of INR 416.18 billion. The enterprise value is 395.22 billion.
Market Cap | 416.18B |
Enterprise Value | 395.22B |
Important Dates
The last earnings date was Tuesday, October 29, 2024.
Earnings Date | Oct 29, 2024 |
Ex-Dividend Date | Nov 7, 2024 |
Share Statistics
GlaxoSmithKline Pharmaceuticals has 169.41 million shares outstanding. The number of shares has decreased by -1.89% in one year.
Current Share Class | n/a |
Shares Outstanding | 169.41M |
Shares Change (YoY) | -1.89% |
Shares Change (QoQ) | +1.57% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 6.73% |
Float | 41.29M |
Valuation Ratios
The trailing PE ratio is 61.66 and the forward PE ratio is 45.33.
PE Ratio | 61.66 |
Forward PE | 45.33 |
PS Ratio | 11.69 |
PB Ratio | 25.28 |
P/TBV Ratio | n/a |
P/FCF Ratio | 44.27 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 38.86, with an EV/FCF ratio of 42.04.
EV / Earnings | 58.55 |
EV / Sales | 11.10 |
EV / EBITDA | 38.86 |
EV / EBIT | 41.21 |
EV / FCF | 42.04 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.01.
Current Ratio | 1.66 |
Quick Ratio | 1.31 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.01 |
Debt / FCF | 0.02 |
Interest Coverage | 554.80 |
Financial Efficiency
Return on equity (ROE) is 42.03% and return on invested capital (ROIC) is 36.91%.
Return on Equity (ROE) | 42.03% |
Return on Assets (ROA) | 17.09% |
Return on Capital (ROIC) | 36.91% |
Revenue Per Employee | 11.09M |
Profits Per Employee | 2.10M |
Employee Count | 3,211 |
Asset Turnover | 1.01 |
Inventory Turnover | 2.62 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.10% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +67.10% |
50-Day Moving Average | 2,697.96 |
200-Day Moving Average | 2,454.00 |
Relative Strength Index (RSI) | 33.18 |
Average Volume (20 Days) | 4,007 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GlaxoSmithKline Pharmaceuticals had revenue of INR 35.60 billion and earned 6.75 billion in profits. Earnings per share was 39.84.
Revenue | 35.60B |
Gross Profit | 21.76B |
Operating Income | 9.59B |
Pretax Income | 9.29B |
Net Income | 6.75B |
EBITDA | 9.99B |
EBIT | 9.59B |
Earnings Per Share (EPS) | 39.84 |
Balance Sheet
The company has 21.11 billion in cash and 147.90 million in debt, giving a net cash position of 20.96 billion or 123.73 per share.
Cash & Cash Equivalents | 21.11B |
Total Debt | 147.90M |
Net Cash | 20.96B |
Net Cash Per Share | 123.73 |
Equity (Book Value) | 16.73B |
Book Value Per Share | 97.18 |
Working Capital | 12.01B |
Cash Flow
In the last 12 months, operating cash flow was 9.71 billion and capital expenditures -312.22 million, giving a free cash flow of 9.40 billion.
Operating Cash Flow | 9.71B |
Capital Expenditures | -312.22M |
Free Cash Flow | 9.40B |
FCF Per Share | 55.49 |
Margins
Gross margin is 61.12%, with operating and profit margins of 26.94% and 18.96%.
Gross Margin | 61.12% |
Operating Margin | 26.94% |
Pretax Margin | 26.10% |
Profit Margin | 18.96% |
EBITDA Margin | 28.07% |
EBIT Margin | 26.94% |
FCF Margin | 26.40% |
Dividends & Yields
This stock pays an annual dividend of 32.00, which amounts to a dividend yield of 1.30%.
Dividend Per Share | 32.00 |
Dividend Yield | 1.30% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 80.23% |
Buyback Yield | 1.89% |
Shareholder Yield | 3.19% |
Earnings Yield | 1.62% |
FCF Yield | 2.26% |
Stock Splits
The last stock split was on September 11, 2018. It was a forward split with a ratio of 2.
Last Split Date | Sep 11, 2018 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |